Paclitaxel-induced pneumonitis in patients with breast cancer: case series and review of the literature

References

• Mekhail TM, Markman M. Paclitaxel in cancer therapy. Exp Opin Pharmacother. 2002;3:755–66.
   PubMedGoogle Scholar
• Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med. 1995;332:1004–14.
   PubMed Web of Science ®Google Scholar
• Foucher P, Camus P. Groupe d'Etude de la Pathologie Pulmonaire Iatrogene. The drug-induced respiratory disease; 2014 [update 2014 June]. Available from: http://www.pneumotox.com.
   Google Scholar
• Ayoub JP, North L, Greer J, Cabanillas F, Younes A. Pulmonary changes in patients with lymphoma who receive paclitaxel. J Clin Oncol. 1997;15:2476.
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, Reddy VV, Holbert JM, Belani CP. Pulmonary infiltrates following administration of paclitaxel. Chest. 1996;110:289–92.
   PubMed Web of Science ®Google Scholar
• Yasuda K, Igishi T, Kawasaki Y, Yamamoto M, Kato K, Matsumoto S, et al. Phase II trial of weekly paclitaxel in previously untreated advanced non-small-cell lung cancer. Oncology. 2003;65:224–8.
   PubMed Web of Science ®Google Scholar
• Yu TK, Whitman GJ, Thames HD, Buzdar AU, Strom EA, Perkins GH, et al. Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients. J Natl Cancer Inst. 2004;96:1676–81.
   PubMedGoogle Scholar
• Taghian AG, Assaad SI, Niemierko A, Kuter I, Younger J, Schoenthaler I, et al. Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel. J Natl Cancer Inst. 2001;93:1806–11.
   PubMedGoogle Scholar
• Kim S, Tannock I, Sridhar S, Seki J, Bordeleau L. Chemotherapy-induced infiltrative pneumonitis cases in breast cancer patients. J Oncol Pharm Pract. 2012;18:311–5.
   PubMedGoogle Scholar
• Wong P, Leung AN, Berry GJ, Atkins KA, Montoya JG, Ruoss SJ, et al. Paclitaxel-induced hypersensitivity pneumonitis: radiographic and CT findings. AJR Am J Roentgenol. 2001;176:718–20.
   PubMed Web of Science ®Google Scholar
• Li J, Juliar B, Yiannoutsos C, Ansari R, Fox E, Fisch MJ, et al. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study. J Clin Oncol. 2005;23(6):1185–91.
   PubMed Web of Science ®Google Scholar
• Graziano SL, Herndon JE 2nd, Socinski MA, Wang X, Watson D, Vokes E, et al. Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901. J Thorac Oncol. 2008;3:158–62.
   PubMed Web of Science ®Google Scholar
• Malik SW, Myers JL, DeRemee RA, Specks U. Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am J Respir Crit Care Med. 1996;154:1851–6.
   PubMed Web of Science ®Google Scholar
• Baselga J, Carbonell X, Castañeda-Soto NJ, Clemens M, Green M, Harvey V, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol. 2005;23:2161–71.
   Web of Science ®Google Scholar
• Abulkhair O, El Melouk W. Delayed paclitaxel-trastuzumab-induced interstitial pneumonitis in breast cancer. Case Rep Oncol. 2011;4:186–91.
   PubMedGoogle Scholar
• Delaunois LM. Mechanisms in pulmonary toxicology. Clin Chest Med. 2004;25:1–14.
   PubMed Web of Science ®Google Scholar
• Kris MG, O'Connell JP, Gralla RJ, Wertheim MS, Parente RM, Schiff PB, et al. Phase I trial of taxol given as a 3-hour infusion every 21 days. Cancer Treat Rep. 1986;70:605–7.
   PubMedGoogle Scholar
• Fujimori K, Yokoyama A, Kurita Y, Uno K, Saijo N. Paclitaxel-induced cell-mediated hypersensitivity pneumonitis. Diagnosis using leukocyte migration test, bronchoalveolar lavage and transbronchial lung biopsy. Oncology. 1998;55:340–4.
   PubMed Web of Science ®Google Scholar
• Sekine I, Kubota K, Tamura Y, Asahina H, Yamada K, Horinouchi H, et al. Innovator and generic cisplatin formulations: comparison of renal toxicity. Cancer Sci. 2011;102:162–5.
   PubMed Web of Science ®Google Scholar
• Nakamura I, Ichimura E, Kobayashi H, Mashiba H, Nagai D, Ebara K, et al. Comparative study of peripheral neurotoxicity after injection of two different paclitaxel formulations in rats. Arzneimittelforschung. 2010;60:205–9.
   PubMed Web of Science ®Google Scholar
• Dang CT, D'Andrea GM, Moynahan ME, Dickler MN, Seidman AD, Fornier M, et al. Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer. Clin Cancer Res. 2004;10:5754–61.
   PubMed Web of Science ®Google Scholar
• Chen YM, Shih JF, Perng RP, Tsai CM, Whang-Peng J. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy. Chest. 2006;129:1031–8.
   PubMed Web of Science ®Google Scholar
• Madarnas Y, Webster P, Shorter AM, Bjarnason GA. Irinotecan- associated pulmonary toxicity. Anticancer Drugs. 2000;11:709–13.
   PubMed Web of Science ®Google Scholar
• Vahid B, Marik P. Pulmonary complications of novel antineoplastic agents for solid tumors. Chest. 2008;133:528–38.
   PubMed Web of Science ®Google Scholar
• Yerushalmi R, Kramer MR, Rizel S, Sulkes A, Gelmon K, Granot T, et al. Decline in pulmonary function in patients with breast cancer receiving dose-dense chemotherapy: a prospective study. Ann Oncol. 2009;20:437–40.
   PubMed Web of Science ®Google Scholar
• Tamiya A, Naito T, Miura S, Morii S, Tsuya A, Nakamura Y, et al. Interstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancer. Anticancer Res. 2012;32:1103–6.
   PubMed Web of Science ®Google Scholar
• Binder D, Hübner RH, Temmesfeld-Wollbrück B, Schlattmann P. Pulmonary toxicity among cancer patients treated with a combination of docetaxel and gemcitabine: a meta-analysis of clinical trials. Cancer Chemother Pharmacol. 2011;68:1575–83.
   PubMed Web of Science ®Google Scholar
• Nagata S, Ueda N, Yoshida Y, Matsuda H, Maehara Y. Severe interstitial pneumonitis associated with the administration of taxanes. J Infect Chemother. 2010;16:340–4.
   PubMed Web of Science ®Google Scholar
• Ostoros G, Pretz A, Fillinger J, Soltesz I, Dome B. Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature. Int J Gynecol Cancer. 2006;16(Suppl 1):391–3.
   PubMed Web of Science ®Google Scholar